Plazomicin for the treatment of multidrug-resistant Klebsiella bacteraemia in a patient with underlying chronic kidney disease and acute renal failure requiring renal replacement therapy

A 75-year-old man presented with shortness of breath and somnolence and was found to have urosepsis. Blood and urine cultures subsequently grew multidrug-resistant (MDR) Klebsiella pneumoniae (Kp) with the New Delhi metallo-β-lactamase gene. The patient was treated successfully with plazomicin and meropenem/vaborbactam combination therapy. The course was complicated by acute kidney injury temporarily requiring haemodialysis, gastrointestinal bleed requiring multiple transfusions and hospital readmission with blood cultures again positive with MDR Kp. Plazomicin drug levels were persistently high during treatment, suggesting that therapeutic drug monitoring may be needed to safely use this drug in patients with severe renal dysfunction. This case marks the first use of plazomicin for bacteraemia in the literature outside of a clinical trial and demonstrates its safe and effective use in a patient with advanced renal disease, and provides important insights about dosing and therapeutic drug monitoring considerations in this patient population.

[1]  Chih-Cheng Lai,et al.  Plazomicin-associated nephrotoxicity. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  G. Stein,et al.  Plazomicin: A New Aminoglycoside. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  K. Krause,et al.  Plazomicin Is Active Against Metallo-β-Lactamase-Producing Enterobacteriaceae , 2019, Open forum infectious diseases.

[4]  E. Simões,et al.  Risk factors and epidemiologic predictors of blood stream infections with New Delhi Metallo-b-lactamase (NDM-1) producing Enterobacteriaceae , 2019, Epidemiology and Infection.

[5]  A. Jubb,et al.  Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae. , 2019, The New England journal of medicine.

[6]  L. Miller,et al.  Once‐Daily Plazomicin for Complicated Urinary Tract Infections , 2019, The New England journal of medicine.

[7]  L. Bry,et al.  Diverse Vectors and Mechanisms Spread New Delhi Metallo-β-Lactamases among Carbapenem-Resistant Enterobacteriaceae in the Greater Boston Area , 2018, Antimicrobial Agents and Chemotherapy.

[8]  K. Krause,et al.  Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae. , 2018, Diagnostic microbiology and infectious disease.

[9]  M. Souli,et al.  Plazomicin: an investigational therapy for the treatment of urinary tract infections , 2015, Expert opinion on investigational drugs.

[10]  D. Nicolau,et al.  Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics , 2015, Infection and drug resistance.

[11]  J. Picazo,et al.  Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii? , 2015, Antimicrobial Agents and Chemotherapy.

[12]  John A Kellum,et al.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury , 2007, Critical care.